Document:

Exhibit 10.1

       

       

Subscription Agreement Number: January , 2019
Issued to: in connection with the Offering by InventaBioTech Inc. of A Minimum of $100,000.000 and a Maximum Principal Amount of
$1,000,000 of Convertible Promissory Notes payable on bearing interest at the annual rate of 12% and convertible into equity securities
of the Company as set forth in the Notes Placement Agent DIVINE CAPITAL MARKETS LLC 39 BROADWAY 36TH FLOOR NEW YORK, NEW YORK 10006
CONFIDENTIAL USE ONLY - MAY NOT BE REPRODUCED NOTICES NONE OF THE NOTES OR THE SECURITIES INTO WHICH THE NOTES WILL BE CONVERTIBLE
(COLLECTIVELY, THE "SECURITIES") HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "SECURITIES ACT"),
OR ANY STATE SECURITIES LAWS. THESE SECURITIES ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS
OF THESE LAWS. THE NOTES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION (THE "COMMISSION")
OR ANY STATE SECURITIES REGULATORY AUTHORITY NOR HAS THE COMMISSION OR ANY SUCH AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF
THE OFFERING OR THE ACCURACY OR ADEQUACY OF THIS SUBSCRIPTION AGREEMENT AND INVESTMENT LETTER AND/OR ANY OTHER INFORMATION DOCUMENTS
PROVIDED BY THE COMPANY IN CONNECTION THEREWITH (COLLECTIVELY, THE "INFORMATION DOCUMENTS"). ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR
ENTITY CREATING THE SECURITIES AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES ARE SUBJECT
TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT,
AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY
WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. CONSEQUENTLY, THE NOTES SHOULD BE
CONSIDERED FOR PURCHASE ONLY AS A LONG-TERM INVESTMENT. THE PURCHASERS SHOULD NOT CONSTRUE THE INFORMATION DOCUMENTS OR ANY COMMUNICATIONS
IN CONNECTION THEREWITH AS LEGAL, TAX OR FINANCIAL ADVICE AND, ACCORDINGLY, MUST CONSULT THEIR OWN LEGAL, ACCOUNTING AND/OR FINANCIAL
ADVISERS WITH RESPECT TO LEGAL, TAX AND RELATED MATTERS CONCERNING THIS INVESTMENT. ANY INVESTOR SEEKING TAX ADVANTAGES SHOULD
NOT PURCHASE NOTES. THIS INVESTMENT IS NOT A TAX SHELTER SINCE IT DOES NOT PROVIDE DEDUCTIONS WHICH WOULD BE AVAILABLE TO REDUCE
INCOME FROM OTHER SOURCES. ACCORDINGLY, A DECISION TO PURCHASE THE NOTES SHOULD BE BASED SOLELY ON HER/HIS EVALUATION OF THE ECONOMIC
CONSIDERATIONS OF THE TRANSACTION. THE INFORMATION DOCUMENTS ARE FOR THE SOLE USE OF, AND CONSTITUTE AN OFFER ONLY TO, THE OFFEREE
WHOSE NAME APPEARS ABOVE. ANY DISTRIBUTION OF THE INFORMATION DOCUMENTS, WHETHER IN WHOLE OR IN PART, TO ANY PERSON OTHER THAN
SUCH OFFEREE AND HER/HIS AUTHORIZED AGENTS, AND ANY REPRODUCTION OF THE INFORMATION DOCUMENTS OR THE DIVULGENCE OF ANY OF THEIR
CONTENTS, IS STRICTLY PROHIBITED. THE OFFEREE NAMED ABOVE, BY ACCEPTING DELIVERY OF THE INFORMATION DOCUMENTS, AGREES TO RETURN
THE INFORMATION DOCUMENTS, TO THE COMPANY, IF SUCH OFFEREE DOES NOT UNDERTAKE TO PURCHASE THE SECURITIES OFFERED HEREBY. NO PERSON
HAS BEEN AUTHORIZED TO MAKE ANY REPRESENTATION OR TO GIVE ANY INFORMATION WITH RESPECT TO THE COMPANY OR THE SECURITIES OFFERED
HEREBY, EXCEPT THE INFORMATION CONTAINED HEREIN (AS AMENDED OR SUPPLEMENTED FROM TIME TO TIME) OR IN THE EXHIBITS HERETO AND, IF
MADE OR GIVEN, SUCH REPRESENTATION OR INFORMATION MUST NOT BE RELIED UPON. IN MAKING THE DECISION WHETHER TO INVEST, PROSPECTIVE
INVESTORS SHOULD RELY ONLY ON INFORMATION CONTAINED IN THE INFORMATION DOCUMENTS OR IN THE EXHIBITS HERETO. NEITHER THE DELIVERY
OF THE INFORMATION DOCUMENTS AT ANY TIME NOR ANY SALE MADE PURSUANT HERETO IMPLIES THAT THE INFORMATION CONTAINED HEREIN IS CORRECT
AS OF ANY TIME SUBSEQUENT TO THE DATE SET FORTH ON THE COVER PAGE HEREOF. THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. CONSEQUENTLY,
ONLY PERSONS WHO CAN AFFORD A TOTAL LOSS OF THEIR INVESTMENT SHOULD CONSIDER THE PURCHASE OF THE NOTES. SUBSCRIBERS WILL BE REQUIRED
TO REPRESENT, AMONG OTHER THINGS, THAT THEY: (A) ARE FULLY FAMILIAR WITH, UNDERSTAND AND CAN BEAR SUCH RISKS; (B) UNDERSTAND ALL
OF THE TERMS OF THIS OFFERING; AND; (C) MEET CERTAIN MINIMUM INVESTMENT AND FINANCIAL SOPHISTICATION CRITERIA. THE INFORMATION
DOCUMENTS DO NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY TO ANY PERSON WHO HAS NOT COMPLETED AND RETURNED
A SUBSCRIPTION AGREEMENT AND A QUALIFIED PURCHASER QUESTIONNAIRE, OR TO ANY PERSON WHOSE PURCHASER REPRESENTATIVE, IF ANY, HAS
NOT COMPLETED AND RETURNED A QUALIFIED PURCHASER REPRESENTATIVE QUESTIONNAIRE, IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY
AND THE PLACEMENT AGENT. THE COMPANY IS MAKING THIS OFFERING ONLY TO "ACCREDITED INVESTORS" AS DEFINED UNDER REGULATION
D UNDER THE SECURITIES ACT AND MAY, IN ITS SOLE AND ABSOLUTE DISCRETION, REFUSE TO ACCEPT ANY SUBSCRIPTION. THE PRICE OF THE NOTES
AND CONVERSION TERMS THEREOF HAVE BEEN ARBITRARILY DETERMINED BY THE COMPANY AND SHOULD NOT BE CONSTRUED AS AN INDICATION OF THE
ACTUAL VALUE OF AN EQUITY INTEREST IN THE COMPANY. THE COMPANY RESERVES THE RIGHT TO WITHDRAW OR AMEND THE TERMS OF THIS OFFERING
AT ANY TIME IN ITS SOLE AND ABSOLUTE DISCRETION, AND TO REJECT ANY SUBSCRIPTION IN WHOLE OR IN PART. THE INFORMATION DOCUMENTS
DO NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY IN ANY JURISDICTION IN WHICH SUCH SALE OR OFFER OR SOLICITATION
WOULD BE PROHIBITED BY LAW. THE COMPANY HEREBY EXTENDS TO EACH PROSPECTIVE INVESTOR THE OPPORTUNITY TO ASK QUESTIONS OF, AND RECEIVE
ANSWERS FROM, ITS OFFICERS CONCERNING THE INFORMATION DOCUMENTS AND TO OBTAIN ANY ADDITIONAL INFORMATION SHE/HE MAY CONSIDER NECESSARY
IN MAKING AN INFORMED INVESTMENT DECISION TO THE EXTENT THAT THE COMPANY POSSESSES SUCH INFORMATION OR CAN ACQUIRE IT WITHOUT UNREASONABLE
EFFORT OR EXPENSE. ACCESS TO SUCH INFORMATION MAY BE OBTAINED BY DIRECTING REQUESTS TO THE PLACEMENT AGENT AT DIVINE CAPITAL MARKETS
LLC, 39 BROADWAY, 36TH FLOOR., NEW YORK, NEW YORK 10006, ATTENTION: DANIELLE HUGHES. THE INFORMATION DOCUMENTS CONTAIN SUMMARIES
OF THE TERMS OF CERTAIN DOCUMENTS, BUT REFERENCE IS HEREBY MADE TO THE ACTUAL DOCUMENTS WHICH MAY BE OBTAINED FROM THE COMPANY
AT THE ADDRESS SET FORTH BELOW FOR COMPLETE INFORMATION CONCERNING THE RIGHTS AND OBLIGATIONS OF THE PARTIES THERETO. ALL SUCH
SUMMARIES ARE QUALIFIED IN THEIR ENTIRETY BY THIS REFERENCE. NOTICE TO FLORIDA RESIDENTS THE SECURITIES REFERRED TO HEREIN WILL
BE SOLD TO, AND ACQUIRED BY INVESTORS IN A TRANSACTION EXEMPT UNDER SECTION 517.061 OF THE FLORIDA SECURITIES INVESTOR PROTECTION
ACT. THE SECURITIES HAVE NOT BEEN REGISTERED UNDER SAID ACT IN THE STATE OF FLORIDA. IN ADDITION, IF SALES ARE MADE TO FIVE OR
MORE FLORIDA RESIDENTS, EACH FLORIDA RESIDENT WHO SUBSCRIBES FOR THE PURCHASE OF INTERESTS HEREIN HAS THE RIGHT, PURSUANT TO SECTION
517.061(11)(A)5 OF SAID ACT, TO WITHDRAW SUCH RESIDENT'S SUBSCRIPTION FOR THE PURCHASE WITHIN THREE BUSINESS DAYS AFTER THE EXECUTION
AND DELIVERY OF THIS AGREEMENT OR PAYMENT FOR THE SECURITIES HAS BEEN MADE, WHICHEVER IS LATER, AND RECEIVE A FULL REFUND OF ALL
MONIES PAID. WITHDRAWAL AND REFUND WILL BE WITHOUT ANY FURTHER LIABILITY TO ANY PERSON. TO ACCOMPLISH THIS WITHDRAWAL, A SUBSCRIBER
ONLY NEED SEND A LETTER OR FACSIMILE TO THE PLACEMENT AGENT, DIVINE CAPITAL MARKETS LLC, 39 BROADWAY, 36TH FLOOR., NEW YORK, NEW
YORK 10006, INDICATING SUCH RESIDENT'S INTENTION TO WITHDRAW. SUCH LETTER MUST BE RECEIVED, PRIOR TO THE END OF THE AFOREMENTIONED
THIRD BUSINESS DAY. IT IS PRUDENT TO SEND SUCH LETTER BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO ENSURE THAT IT IS RECEIVED
AND ALSO TO EVIDENCE THE TIME IT WAS MAILED, UNLESS SAME IS PERSONALLY DELIVERED. IF THE REQUEST IS MADE VERBALLY IN PERSON OR
BY TELEPHONE TO DANIELLE HUGHES AT THE ABOVE ADDRESS, A WRITTEN CONFIRMATION THAT THE REQUEST HAS BEEN RECEIVED SHOULD BE REQUESTED.
THE COMPANY'S ADDRESS IS 3463 MAGIC DRIVE, SUITE 120, SAN ANTONIO, TX 78229, ATTENTION: JAMES GARVIN. ITS TELEPHONE NUMBER IS 210.767.2727.
INVENTABIOTECH INC. TABLE OF CONTENTS Title of Section Page 1. Terms of the Offering 1 2. The Placement Agent 3 3. Suitability
Requirements; Transferability 3 4. Subscription Procedure and Effect 4 5. The Company's Representations, Warranties and Covenants
5 6. Validity of Securities 10

7. Indemnity 11 9. Modification 11 10. Notices
11 11. Counterparts 11 12. Successors and Assigns 11 13. Transferability 12 14. Applicable Law 12 15. Gender 12 16. Severability
12 Subscription Signature Section EXHIBITS Exhibit A: Form of Note Exhibit B: Form of Purchaser Questionnaire i SUBSCRIPTION AGREEMENT
AND INVESTMENT LETTER Date: January 9, 2019 Divine Capital Markets LLC 39 Broadway, 36th Floor New York, New York 10006 Attention:
Danielle Hughes Re: Subscription to Purchase Notes of InventaBioTech Inc. To the Board of Directors of InventaBioTech Inc.: This
Subscription Agreement and Investment Letter (this "Subscription Agreement") is being delivered to the purchaser identified
on the signature page to this Agreement (the "Undersigned" or "Subscriber") in connection with its investment
in the securities of InventaBioTech Inc. a Colorado corporation (the "Company"). The Company is conducting a private
placement (the "Offering") of a minimum principal amount of $100,000 and a maximum principal amount of $1,000,000 of
Convertible Promissory Notes (the "Notes"), each of which is convertible into: (i) units (the "Units") consisting
of the Company's equity securities the Company plans to offer for sale in a private financing transaction or (ii) shares of Common
Stock of the Company, $0.001 par value per share (the "Common Stock"), on terms set forth in the Notes. For purposes
of this Agreement, the term "Securities" shall refer to the Notes and to: (i) the Units into which they may be converted
or (ii) the Common Stock into which they may be converted (collectively, the "Underlying Securities"). This will acknowledge
that the Subscriber hereby agrees to irrevocably purchase from the Company a Note in the principal amount set forth in the Subscription
Signature Section below in accordance with the terms of this Subscription Agreement. 1. Terms of the Offering. The Offering is
being made on a "best efforts, all or none" basis with respect to the first $100,000 in principal amount of the Notes,
and, thereafter, on a "best efforts only" basis until the remaining $9000,000 in principal amount of the Notes is sold,
the Company terminates the Offering, which it can do in its complete discretion at any time, or the Offering Period, as hereinafter
defined, expires, whichever occurs first (the "Termination Date"). Unless at least $100,000 in principal amount of the
Notes (the "Minimum") is sold on or before February 28, 2019, or March 31, 2019 if extended by the Company and the Placement
Agent (the "Offering Period") and paid for with collected funds received in escrow as noted in the next succeeding paragraph
within two Business Days thereafter, the Offering will terminate and all funds collected from subscribers will be promptly returned
to them without interest thereon or deduction therefrom. A "Business Day" means any day except Saturday, Sunday and any
day that shall be a federal legal holiday or a day on which banking institutions in the State of New York are authorized or required
by law or other governmental action to close. Persons affiliated and/or otherwise related to the Company, including existing shareholders,
may purchase Notes in the Offering and the Notes purchased by them will be included in the number of Notes needed to satisfy the
Minimum. The Placement Agent and persons affiliated with it also may purchase Notes in the Offering but the Notes purchased by
them will not be included in the number of Notes needed to satisfy the Minimum. Because the Minimum of $100,000 in principal amount
of the Notes must be sold in order to make the Offering effective, all funds received will be held in escrow with JP Morgan Chase
Bank (the "Escrow Agent"). No funds will be remitted to the Company until at least $100,000 in principal amount of the
Notes has been sold and paid for. Thereafter, funds will continue to be held in escrow and released to the Company at each subsequent
closing, which shall be at the discretion of the Company and the Placement Agent and each of which shall occur prior to the earlier
of: (i) February 28, 2019, which date may be extended to March 31, 2019, by agreement between the Company and the Placement Agent;
or (ii) when all $1,000,000 in principal amount of the Notes on has been sold and paid for (each a "Closing" and, collectively,
the "Closings") against delivery of the appropriate number of subscribed Notes. Each Closing of the purchase and sale
of the Notes following acceptance by the Company of subscriptions, as evidenced by the Company's execution of the applicable Subscription
Agreements, shall take place at the Placement Agent's offices, or such other place as the Placement Agent and the Company shall
determine, on such date as the Placement Agent and the Company shall determine. The date on which a Closing is consummated is the
"Closing Date." The Offering is being made only to "accredited investors" as defined under Regulation D under
the Securities Act. It is being conducted pursuant to the exemption from the registration provisions of the Securities Act set
forth in Section 4(a)(2) thereof and applicable Rules and Regulations promulgated thereunder, including Rule 506(b) of Regulation
D. Section 4(a)(2) requires, among other things, that each purchaser acquire the Notes and Underlying Securities with investment
intent and not with a view to distribution. The Notes being offered hereby and the Underlying Securities will be "restricted
securities" under the Securities Act and may not be resold publicly except in compliance with Rule 144 promulgated thereunder
or unless subsequently registered. Although the Common Stock is traded on the OTC Pink marketplace there is no public market for
the Notes and it is not anticipated that a public trading market for them will ever develop. The Company's common stock is listed
under the symbol "INVB." ACCORDINGLY, THE UNDERSIGNED UNDERSTANDS AND ACKNOWLEDGES THAT, EVEN AFTER THE TERMINATION OF
THE RESALE RESTRICTION PERIODS ON THE NOTES AND THE UNDERLYING SECURITIES, AND/OR THE COMMON STOCK UNDERLYING THE UNITS ARE REGISTERED,
SHE/HE MAY BE UNABLE TO RESELL THESE SECURITIES FOR A SIGNIFICANT PERIOD OF TIME, IF EVER AND THERE IS NO ASSURANCE THAT THE NOTES
WILL BE REPAID IN ACCORDANCE WITH THEIR TERMS IF EVER. Execution of this Subscription Agreement shall constitute an offer by the
Undersigned to purchase the number of Notes set forth in the Subscription Signature Section below on the terms 2 specified herein.
If the Undersigned's offer is accepted, the Company will execute a copy of the Signature Section and return it to the Undersigned.
2. The Placement Agent. The Placement Agent, a member firm of the Financial Industry Regulatory Authority ("FINRA"),
is acting as the exclusive placement agent for the Company in placing this Offering. If all of the Notes are sold, the Company
will receive gross proceeds of $1,000,000 less the Placement Agent's expenses. Management estimates that the Placement Agent's
expenses, including the fee and expense allowance payable to the Placement Agent described below, will be approximately $110,000
if the Offering is fully sold. The Placement Agent will receive a fee equal to 8%, and a non-accountable expense allowance up to
3% of the aggregate gross purchase price of the Notes sold. The Company will also grant to the Placement Agent, for nominal consideration,
a warrant, exercisable over a five- year period commencing on the final Closing Date of the Offering, to purchase such number of
Notes as shall equal 8% of the number of Notes sold in the Offering at an exercise price equal to $0.20. The undersigned understands
that, except as may be required by applicable regulations of FINRA, the Placement Agent has not independently verified the information
provided to her/him with respect to the Company. Accordingly, there is no representation by the Placement Agent as to the completeness
or accuracy of such information. 3. Suitability Requirements; Transferability. An investment in the Company involves a high degree
of risk and is suitable only for those qualified persons who have substantial financial resources and who, alone or together with
their purchaser representatives (see the definition below), have such knowledge and experience in financial and business matters
that they are capable of evaluating the merits and risks of purchasing the Notes. Satisfaction of these suitability standards by
a person does not represent a determination by the Company that the Notes are a suitable investment for such person. Each person
must consult such person's own professional advisors in order to determine the suitability of the investment. The Company may make
or cause to be made such further inquiry and obtain such additional information as it deems appropriate with regard to the suitability
of prospective investors. Because this Offering is being made only to accredited investors, the Undersigned must complete, sign
and return a Purchaser Questionnaire to the Company in order to assist it in determining whether the Undersigned is an accredited
or sophisticated investor and satisfies the minimum suitability requirements. The form of Purchaser Questionnaire is attached hereto
as Exhibit B. The term "purchaser representative" means any person who satisfies all of the following conditions or who
the Company reasonably believes satisfies all of the following conditions: (a) she/he is not an affiliate, director, officer or
other employee of the Company or beneficial owner of 10% or more of any class of the Company's equity securities, except where
the purchaser is: 3 (1) A relative of the purchaser representative by blood, marriage or adoption and not more remote than a first
cousin; (ii) A trust or estate in which the purchaser representative and any persons related to her/him as specified in Paragraph
(h)(1)(i) or (h)(1)(iii) of Rule 501 under Regulation D, collectively have more than 50 percent of the beneficial interest (excluding
contingent interest) or of which the purchaser representative serves as trustee, executor, or in any similar capacity; or (iii)
A corporation or other organization of which the purchaser representative and any persons related to her/him as specified in Paragraph
(h)(1)(i) or (h)(1)(ii) of Rule 501, collectively are the beneficial owners of more than 50 percent of the equity securities (excluding
directors' qualifying shares) or equity interests; (b) she/he has such knowledge and experience in financial and business matters
that she/he is capable of evaluating, alone, or together with other purchaser representatives of the purchaser or together with
the purchaser, the merits and risks of the prospective investment; (c) she/he is acknowledged by the purchaser in writing, during
the course of the transaction, to be her/his purchaser representative in connection with evaluating the merits and risks of the
prospective investment; and (d) she/he discloses to the purchaser in writing prior to the acknowledgment specified in Paragraph
(h)(3) of Rule 501, any material relationship between herself/himself or her/his affiliates and the Company or its affiliates that
then exists, that is mutually understood to be contemplated or that has existed at any time during the previous two years and any
compensation received or to be received as a result of such relationship. If the Undersigned is using a purchaser representative,
the purchaser representative must complete, execute and return a Purchaser Representative's Questionnaire to the Company. A form
of Purchaser Representative's Questionnaire is attached hereto as Exhibit C. 4. Subscription Procedure and Effect. The subscription
price shall be payable upon execution of this Subscription Agreement in accordance with the terms set forth herein. In order to
subscribe for the Notes, a qualified prospective investor must deliver the following to the Placement Agent, at 39 Broadway, 36th
Floor, New York, New York 10006, Attention Danielle Hughes. • an executed copy of the Subscription Signature Section of this
Subscription Agreement, with all blanks properly completed, indicating all of the Notes subscribed for; • an executed copy
of a Purchaser Questionnaire, with all questions properly completed; and • if applicable, an executed copy of a Purchaser
Representative Questionnaire, with 4

all questions properly completed; a certified
check, bank draft or money order, in the amount of the purchase price for the Notes to be purchased, payable to JPMorgan Chase
Bank for "InventaBioTech Inc." Wired funds are also acceptable. The Company would prefer that the funds be wired. The
wiring instructions are: JPMorgan Chase Bank; 28 Liberty Street, NY, NY 10005 ROUTING NUMBER: 021 000 021 SWIFT/BIC Code CHASUS33
ACCOUNT NAME: DCM FBO of Investors of InventaBioTech Inc.; ACCOUNT NUMBER: 3768635808 On delivery of the executed Subscription
Signature Section of this Subscription Agreement, the Subscriber will become bound by its terms. Unless otherwise required by applicable
state securities laws, the Subscriber may not withdraw or revoke her/his executed Subscription Agreement in whole or in part without
the consent of the Company. The Company may accept this Subscription Agreement at any time on or before the Termination Date. This
Subscription Agreement is not binding on the Company until it is accepted as evidenced by the signature of an officer of the Company.
The Company, in its sole discretion, has the right to accept or reject this Subscription Agreement in whole or in part and accept
Subscription Agreements other than in the order received. In the event of rejection of this Subscription Agreement, or in the event
that, for any reason, none of the Notes are sold (in which case this Subscription Agreement will be deemed to be rejected), the
Company will thereafter promptly return or cause to be returned to the Subscriber by mail, a check in the amount paid by the Subscriber
in this Offering, without interest thereon or deduction therefrom for expenses or otherwise, and this Subscription Agreement shall
thereafter have no further force or effect except for the provisions of Section 7. 5. The Company's Representations, Warranties
and Covenants. The Company represents, warrants and covenants to the Undersigned and the Placement Agent that: (a) Subsidiaries.
The Company has no direct or indirect subsidiaries other than those set forth in the SEC Documents, as defined below in Subsection
5(e), (individually a "Subsidiary" and, collectively, the "Subsidiaries"). Except as disclosed in the SEC Documents,
the Company owns, directly or indirectly, all of the capital stock of each Subsidiary free and clear of any and all liens, charges,
encumbrances, security interests, rights of first refusal or other restrictions of any kind (each a "Lien" and, collectively,
"Liens"), and all the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully
paid, non-assessable and free of preemptive and similar rights. (b) Organization and Qualification. Each of the Company and each
Subsidiary is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or organization (as applicable), with the requisite power and authority to own and use its properties and
assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation of any of the
provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter 5 documents. Each
of the Company and each Subsidiary is duly qualified to conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, could not, individually or in the aggregate,
have or reasonably be expected to result in (i) an adverse effect on the legality, validity or enforceability of any agreement
or other document executed by the Company relating to the Offering (each a "Transaction Document" and, collectively,
the "Transaction Documents"), (ii) a material and adverse effect on the results of operations, assets, prospects, business
or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) an adverse impairment to
the Company's ability to perform on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a
"Material Adverse Effect"). (c) Authorization; Enforcement. The Company has the requisite corporate power and authority
to enter into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its
obligations thereunder. The execution and delivery of each of the Transaction Documents by the Company and the consummation by
it of the transactions contemplated thereby have been duly authorized by all necessary corporate action on the part of the Company
and no further corporate action is required by the Company in connection therewith. Each Transaction Document has been (or upon
delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as rights
to indemnity and contribution may be limited by state or federal securities laws or the public policy underlying such laws, except
as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors'
and contracting parties' rights generally and except as enforceability may be subject to general principles of equity (regardless
of whether such enforceability is considered in a proceeding in equity or at law). (d) No Conflicts. The execution, delivery and
performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated thereby
do not and will not (i) conflict with or violate any provision of the Company's or any Subsidiary's certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. (e) Representations
and Warranties relating to the SEC Documents. The Company has filed all reports, schedules, forms, statements and other documents
(collectively, the "SEC 6 Documents") required to be filed by it with the Commission pursuant to the Securities Exchange
Act of 1934 (the "Exchange Act") within the past three years. The SEC Documents have complied in all material respects
with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder applicable to
the SEC Documents, and none of the SEC Documents, at the time they were filed with the Commission, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, to the best of
the Company's knowledge during those respective dates, the Company's financial statements included in the SEC Documents complied
as to form in all material respects with applicable accounting requirements and the published rules and regulations of the Commission
with respect thereto. Such financial statements have been prepared in accordance with accounting principles generally accepted
in the United States as in effect from time to time, consistently applied ("GAAP"), during the periods involved (except
(a) as may be otherwise indicated in such financial statements or the notes thereto, or (b) in the case of unaudited interim statements,
to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects
the Company's financial condition as of the respective dates thereof and the results of the Company's operations and cash flows
for the respective periods then ended (subject, in the case of unaudited statements, to normal year- end audit adjustments). The
Company has not received notification from the Commission, and/or any federal or state securities bureaus that any investigation
(informal or formal), inquiry or claim is pending, threatened or in process against the Company and/or relating to any of its securities.
(f) Material Changes. Since the date of the latest audited financial statements included within the SEC Documents, except as specifically
disclosed in the SEC Documents, (i) there has been no event, occurrence or development that has had or is reasonably likely to
result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A)
trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice, and (B) liabilities
not required to be reflected in the Company's financial statements pursuant to GAAP or required to be disclosed in filings made
with the Commission, (iii) the Company has not altered its method of accounting or the identity of its auditors, (iv) the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its capital stock, and (v) the Company has not issued any equity securities
to any officer, director or affiliate, except pursuant to existing Company stock option or stock purchase plans or disclosed in
SEC Documents. Except as specified in the SEC Documents, the Company does not have pending before the Commission any request for
confidential treatment of information (g) Litigation. Except as disclosed in the SEC Documents, (i) there is no action, suit, inquiry,
notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation pending or threatened
in writing against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency, regulatory authority (federal, state, county, local or foreign), stock market, stock exchange
or trading facility (individually an "Action" and, collectively, "Actions"), which (A) adversely affects or
challenges the legality, validity or enforceability of any of the Transaction Documents or the Notes or Underlying Securities or
(B) could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be expected to result in
a Material Adverse Effect, (ii) neither the Company nor any Subsidiary, nor any director or officer thereof, 7 is or has been the
subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach
of fiduciary duty, and (iii) there has not been, and to the knowledge of the Company, there is not pending or contemplated, any
investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or
any Subsidiary under the Exchange Act or the Securities Act. (h) Employment Matters. The Company and the Subsidiaries are in compliance
with all federal, state, local and foreign laws and regulations respecting employment and employment practices, terms and conditions
of employment and wages and hours except where failure to be in compliance would not have a Material Adverse Effect. Neither the
Company nor any Subsidiary is bound by or subject to (and none of the Company's or any of its Subsidiaries' assets or properties
are bound by or subject to) any written or oral, express or implied, contract, commitment or arrangement with any labor union,
and no labor union has requested or, to the Company's knowledge, has sought to represent any of the employees, representatives
or agents

of the Company or the Subsidiaries. There is
no strike or other material labor dispute involving the Company or the Subsidiaries pending, or to the Company's knowledge, threatened,
that could have a Material Adverse Effect nor is the Company aware of any labor organization activity involving its or its Subsidiaries'
employees. The Company is not aware that any officer or key employee intends to terminate her or his employment with the Company,
nor does the Company have a current intention to terminate the employment of any officer or key employee. (i) Compliance. Neither
the Company nor any Subsidiary (i) is in default under or in violation of (and no event has occurred that has not been waived that,
with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit
agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether
or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body,
or (iii) is or has been in violation of

 

    
    
      	 		 

    

  
    
   
 

any statute, rule or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection,
occupational health and safety, product quality and safety and employment, labor matters and gaming matters, except in each case
as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. The Company
is in compliance with the applicable requirements of the Sarbanes-Oxley Act of 2002 and the rules and regulations thereunder promulgated
by the Commission, except where such noncompliance could not have or reasonably be expected to result in a Material Adverse Effect.
(j) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC
Documents, except where the failure to possess such permits would not, individually or in the aggregate, have or reasonably be
expected to result in a Material Adverse Effect (each a "Material Permit"), and neither the Company nor any Subsidiary
has received any notice of proceedings relating to the revocation or modification of any Material Permit. 8 (k) Title to Assets.
The Company and the Subsidiaries have good and marketable title in all personal property owned by them that is material to their
respective businesses, in each case free and clear of all Liens. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and, to the Company's knowledge, enforceable leases of which the
Company and the Subsidiaries are in compliance, except as could not, individually or in the aggregate, have or reasonably be expected
to result in a Material Adverse Effect. (1) Patents and Trademarks. The Company and the Subsidiaries have, or have rights to use,
all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses and other
similar rights that are necessary or material for use in connection with their respective businesses as described in the SEC Documents
and which the failure to so have could, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect (collectively, the "Intellectual Property Rights"). Neither the Company nor any Subsidiary has received
a written notice that the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the rights
of any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind (a "Person").
To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by
another Person of any of the Intellectual Property Rights. (m) Insurance. The Company and the Subsidiaries are insured by insurers
of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses
in which the Company and the Subsidiaries are engaged. The Company does not believe that it will be unable to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business without a material increase in cost. (n) Transactions With Affiliates and Employees. Other than set forth
in the SEC Documents, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees
of the Company is currently a party to any transaction with the Company or any Subsidiary (other than for services as employees,
officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee or partner. (o) Certain Fees. Except for transactions with the Placement Agent, no
brokerage or finder's fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant,
finder, placement agent, investment banker, bank or other Person with respect to the transactions related to the Offering. (p)
Investment Company. The Company is not, and is not an affiliate of, an "investment company" within the meaning of the
Investment Company Act of 1940. 9 (q) Taxes. Other than federal payroll taxes in the approximate amount of $110,000 that are currently
past due, the Company and the Subsidiaries have timely made or filed all federal, state and foreign income and all other tax returns,
reports and declarations required by any jurisdiction to which the Company or such Subsidiaries are subject (unless and only to
the extent that the Company or such Subsidiaries have set aside on their books provisions reasonably adequate for the payment of
all unpaid and unreported taxes) and have timely paid all taxes and other governmental assessments and charges that are material
in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith,
and have set aside on their books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods
to which such returns, reports or declarations apply. To the Company's knowledge, there are no unpaid taxes of the Company and
the Subsidiaries in any material amount claimed to be due by the taxing authority of any jurisdiction. Neither the Company nor
the Subsidiaries have executed a waiver with respect to the statute of limitations relating to the assessment or collection of
any foreign, federal, state or local tax. None of the Company's or any of its Subsidiaries' tax returns is currently being audited
by any taxing authority. (r) Disclosure. The Company confirms that neither it, nor to its knowledge, any other Person acting on
its behalf has provided any prospective purchasers of the Securities or their agents or counsel with any information that the Company
believes constitutes material, non-public information. The Company understands and confirms that the prospective purchasers will
rely on the foregoing representations and covenants in effecting transactions in securities of the Company. All disclosure provided
to the prospective purchasers regarding the Company, its business and the transactions contemplated hereby, furnished by or on
behalf of the Company (including the Company's representations and warranties set forth in this Subscription Agreement) are true
and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
(s) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other Person acting on behalf
of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful
expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials
or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company (or made by any Person acting on its behalf of which the Company is aware) which is in violation
of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 6. Validity
of Securities. The Company represents and warrants to the Undersigned that the Notes have been duly authorized and, when issued
and paid for in accordance with the terms of the Transaction Documents, will be the binding obligations of the Company payable
in accordance with their terms and free and clear of all liens, other than restrictions on transfer provided for in the Transaction
Documents or imposed by applicable securities laws. The shares of Common Stock issuable upon conversion of the Notes have been
and the Units and securities underlying the Units will be duly authorized and when issued in accordance with the terms of the conversion
provisions of the Notes, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens, other than
restrictions on transfer provided for in the Transaction 10 Documents or imposed by applicable securities laws, and shall not be
subject to preemptive or similar rights of stockholders. Assuming the accuracy of the representations and warranties of the Purchasers
in this Agreement, the Securities will be issued in compliance with all applicable federal and state securities laws. 7. Indemnity.
The Subscriber agrees to indemnify and hold harmless the Company, the Placement Agent, and their respective officers, directors,
employees, attorneys and agents, and any other Persons authorized by the Company to participate in the offer and/or sale of the
Notes against any and all loss, liability, claim, damage and expenses (including, but not limited to, any and all expenses reasonably
incurred in investigating, preparing or defending against litigation commenced or threatened or any claim whatsoever) arising out
of or based upon any breach of or failure by the Subscriber to comply with any representation, warranty, covenant or agreement
made by the Subscriber herein or in any other document furnished by the Subscriber to any of the foregoing in connection with this
transaction. 8. Representation and Covenant Relating to Short Sales. The Purchaser represents that she/he has never held a short
position in the Company's Common Stock and covenants that she/he will never short the Common Stock as long as she/he owns the Common
Stock or securities convertible into shares of the Company's Common Stock. 9. Modification. Neither this Subscription Agreement
nor any provisions hereof shall be modified, changed, discharged or terminated except by an instrument in writing signed by the
party against whom any waiver, change, discharge or termination is sought. 10. Notices. All notices, consents, requests, demands,
offers, reports and other communications required or permitted to be given pursuant to this Subscription Agreement shall be in
writing and shall be considered properly given or made when personally delivered to the party entitled thereto, or when sent by
a nationally recognized overnight delivery service, confirmed electronic or facsimile transmission, or by United States mail in
a sealed envelope, with postage prepaid, addressed, if to the Company, to the address given above, and if to the Subscriber, to
the address set forth opposite the Subscriber's signature on the counterpart of this Subscription Agreement that the Subscriber
originally executes and delivers to the Company. The Company may change its address by giving notice thereof to all Note purchasers.
11. Counterparts. This Subscription Agreement may be executed in multiple counterpart copies, each of which shall be considered
an original and all of which shall constitute one and the same instrument

binding on all the parties, notwithstanding
that all parties are not signatories to the same counterpart. 12. Successors and Assigns. This Subscription Agreement and all of
the terms and provisions hereof shall be binding upon and inure to the benefit of the parties and their respective heirs, executors,
administrators, successors, trustees, legal representatives and assigns. If the Subscriber is more than one person, the obligation
of the Subscriber shall be joint and several and the agreements, representations, warranties and acknowledgments herein contained
shall be deemed to be made by and be binding upon each such person and her/his heirs, executors, administrators, successors, trustees,
legal representatives and assigns. 11 13. Transferability. The Undersigned may not transfer or assign this Subscription Agreement
or any interest of the Undersigned's herein and any attempt to effect such a transfer shall be void. The assignment and transferability
of the Notes and Underlying Securities acquired by the Undersigned pursuant hereto shall be made only in accordance with the provisions
of this Subscription Agreement, the Securities Act and the Rules and Regulations promulgated thereunder and applicable state securities
laws. 14. Applicable Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State
of New York applicable to contracts made and to be performed entirely within such State. 15. Gender. The use herein of the masculine
pronouns or similar terms shall be deemed to include the feminine and neuter genders as well and vice versa and the use of the
singular pronouns shall be deemed to include the plural as well and vice versa. 16. Severability. If one or more of the provisions
or portions of this Subscription Agreement shall be deemed by any court or quasi-judicial authority to be invalid, illegal or unenforceable
in any respect, the invalidity, illegality or unenforceability of the remaining provisions, or portions of provisions contained
herein shall not in any way be affected or impaired thereby. 12 SUBSCRIPTION SIGNATURE SECTION INVENTABIOTECH INC. JANUARY , 2019
SUBSCRIPTION AGREEMENT AND INVESTMENT LETTER The undersigned (the "Undersigned" or "Subscriber") hereby purchases
a Note in the principal amount of $ from InventaBioTech Inc. (the "Company") pursuant to the terms of the Subscription
Agreement and Investment Letter dated January , 2019 (the "Subscription Agreement") of which this Subscription Signature
Section is a part. All terms in this Subscription Signature Section have the meanings defined elsewhere in this Subscription Agreement.
Subscriber Representations. The Subscriber hereby acknowledges, represents and warrants to, and agrees with the Company as follows:
(a) The Subscriber is acquiring the Note and any Underlying Securities for which the Note may be converted for the Subscriber's
own account as principal for investment and not with a view to resale, distribution or fractionalization in whole or in part, and
has no current agreement, understanding or arrangement to subdivide, sell, assign or otherwise dispose of all or any part of the
Note and/or Underlying Securities and understands that there is no public market for the Notes, and none is expected to develop
in the foreseeable future, if ever. She/he does not have any contract, undertaking, agreement or arrangement with any Person to
sell, transfer or grant participations to such Person or to any third Person, with respect to the Note and/or Underlying Securities
for which she/he is subscribing. (b) The Note that the Subscriber is purchasing and the Underlying Securities for which the Note
may be converted have not been registered under the Securities Act or qualified under applicable state securities laws and the
registration provisions of the Securities Act as well as the qualification provisions of such state laws thereof restrict their
transferability. Based upon the representations and agreements being made by her/him herein, the Subscriber acknowledges that the
offering and sale of the Notes are intended to be exempt from registration under the Securities Act by virtue of Section 4(a)(2)
thereof and applicable Rules and Regulations adopted thereunder, and that: 1. the Undersigned's Note and Underlying Securities
cannot be sold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Securities Act and
qualified under applicable state securities laws or, in the reasonable opinion of the Company's counsel, an exemption from such
registration and/or qualification is available; 2. Sales or transfers of the Undersigned's Note and Underlying Securities are further
restricted by the provisions of state securities laws; 3. the Company is under no obligation to assist the Undersigned in complying
with any exemption from registration under the Securities Act or qualification under any state securities law; 13 4. the certificates
or other documentation representing the Undersigned's Note and Underlying Securities will bear, in substance, the following legend:
NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE "SECURITIES
ACT"), AND ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT; 5. the Company will place stop-transfer instructions on its books and with the transfer agent of its securities with respect
to the Note and Underlying Securities registered in the name of the Undersigned or beneficially owned by her/him. The Undersigned
further acknowledges that the basis for these exemptions may not be available if, notwithstanding such representations, she/he
only intends to hold these securities for a fixed or determinable period in the future, or until the market price rises or falls
and she/he hereby represents and warrants that she/he does not have any such intention. (c) The Subscriber: (A) by herself/himself
or together with her/his Purchaser Representative, if any, has such knowledge and experience in financial, business and tax matters
that she/he is capable of evaluating the merits of the prospective purchase of the Note and making an investment decision with
respect to the Company; (B) has had substantial experience in previous private and public purchases of speculative securities and
is not relying on the Company, the Placement Agent, or any of their respective affiliates or attorneys with respect to economic,
tax or other considerations involved in this investment; and (C) is able to bear the economic risk of this investment (i.e., she/he
can afford a complete loss of her/his investment). In this regard, her/his overall commitment to investments, which are not readily
marketable, is not disproportionate to her/his net worth, and her/his purchase of the Note will not cause such overall commitment
to become excessive. (d) The Subscriber understands and acknowledges that an investment in the Company is speculative and subject
to many risks. In this regard, the Company cannot assure her/him that all of the Notes will be sold. Accordingly, the Company's
operations and financial condition will be adversely affected to the extent that less than all of the Notes are sold, especially
because it currently has no commitment for any financing. (e) (insert name of Purchaser Representative: if none, leave blank) has
acted as the Undersigned's Purchaser Representative for purposes of the private placement exemption under the Securities Act. If
the Undersigned has appointed a Purchaser Representative (which term is used herein with the same meaning as given in Rule 501(h)
of Regulation D), she/he has been advised by her/his Purchaser Representative as to the merits and risks of an investment in the
Company in general and the suitability of the Note as an investment for the Undersigned in 14 particular, and is aware that the
Purchaser Representative may be receiving compensation from the Company in connection with the services being performed by such
Purchaser Representative for the Undersigned relating to her/his purchase of the Note. (f) The Subscriber has reviewed carefully
the definition of "accredited investor" as set forth below, and the particular subparagraph or subparagraphs by which
the Undersigned qualifies as such is (are) checked by her/him below. THE UNDERSIGNED UNDERSTANDS THAT, IF THE OFFERING IS CONSUMMATED,
SHE/HE COULD LOSE HER/HIS ENTIRE INVESTMENT. (balance of this page left blank intentionally) 15

    	 

    	 

    

 

 

 

Definition of Accredited
Investor The Undersigned represents that she/he is an "accredited investor" as that term is defined in Rule 501 (a)
of Regulation D promulgated under the Securities Act as follows (CHECK APPLICABLE BOXES): (A) Certain banks, savings and loan
institutions, broker-dealers, investment companies and other entities including an employee benefit plan within the meaning of
Title I of the Employee Retirement Income Security Act of 1974 with total assets in excess of $5,000,000; any private business
development company as defined in Section 202 (a) (22) of the Investment Advisers Act of 1940; any organization described in Section
501 (c) (3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for
the specific purpose of acquiring the Note, with total assets in excess of $5,000,000; or any trust with total assets in excess
of $5,000,000 not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated
person as described in Section 230.506 (b) (2) (ii) of Regulation D; (B) Any natural person whose individual net worth, or joint
net worth with that person's spouse, at the time of her/his purchase exceeds $1,000,000 excluding the value of that person's personal
residence; (C) Any natural person who had an individual income in excess of $200,000 or, with that person's spouse a joint income
in excess of $300,000 in each of the two most recent years and who reasonably expects an income in excess of $200,000, or $300,000
with that person's spouse, in the current year; (D) Any Individual Retirement Account and the individual who established the IRA
is an accredited investor on the basis of (B) or (C) above; (E) Any director, executive officer or general partner of the issuer
of the securities 5Fing offered or sold, or any director, executive officer or general partner of a general partner of that issuer;
or (F) Any entity in which all of the equity owners are accredited investors under any of the paragraphs above. In connection
with the foregoing representations the Undersigned has appended hereto as Exhibit B, a Purchaser Questionnaire that she/he has
completed and executed. She/he represents and warrants that the information set forth therein as well as all other information
which she/he is furnishing to the Company with respect to her/his financial condition and business and investment experience is
accurate and complete as of the date hereof and she/he covenants that, in the event a material change should occur in such information,
she/he will immediately provide the Company with such revised or corrected information. (h) The Subscriber has adequate means
of providing for her/his current needs and possible personal contingencies, has no need for liquidity of this investment and has
no reason to anticipate any change in personal circumstances, financial or otherwise, which might cause or require any sale or
distribution of the Note and/or Underlying Securities. 16 (1) The Subscriber is familiar with the nature of the risks attending
investments in securities and has determined that the purchase of the Note is consistent with her/his investment objectives and
income prospects. (j) The Subscriber's purchase of the Note has not been solicited by means of general solicitation or general
advertisement, and the Subscriber has not been furnished with any oral representation or oral information in connection with the
Offering which is not set forth herein or in the Exhibits hereto or in the SEC Documents. (k) The Subscriber has received, reviewed
and understands this Subscription Agreement, including all of the Exhibits attached hereto, has reviewed the SEC Documents, and
has been granted a reasonable time prior to the date hereof during which she/he has had the opportunity to obtain such additional
information as she/he deemed necessary to permit her/him to make an informed decision with respect to the purchase of her/his
Note. She/he also represents and warrants that she/he (A) has reviewed such other documents and obtained such other information
from the Company as she/he deems necessary in order for her/him to make an informed investment decision; (B) has had access to
all relevant documents, instruments, books, and other records of or pertaining to the Company and has had the opportunity to ask
questions of and receive answers from management and other representatives of the Company and requires no additional information
or documentation; and (C) is fully aware of the current business prospects, financial condition, and operating history as set
forth herein and in the Exhibits hereto and in the SEC Documents relating to the Company. (1) Other than information given to
the Subscriber as described in Paragraph (k) above, no representations or warranties have been made to the Undersigned by the
Company, the Placement Agent or any other Person in connection with this Offering, or any officer, employee, agent or affiliate
of the Company or the Placement Agent, other than the representations made by the Company set forth herein and she/he is not relying
upon any representations other than those described in this paragraph or in Paragraph (kLabove. (m) The Subscriber is not relying
on the Company, the Placement Agent or this Subscription Agreement with respect to individual tax and other economic considerations
involved in this investment and acknowledges that her/his investment in the Company is not a tax shelter. (n) If for any reason
this Offering does not close or the Company does not accept the Undersigned's subscription, the Undersigned shall have no claims
against the Company, the Placement Agent, or their respective officers, directors, employees, attorneys or affiliates, and shall
have no interest in the Notes, the Underlying Securities or the Company. (o) If the Subscriber is a corporation, limited liability
company, partnership, trust or other entity: (A) it is authorized and qualified to become a creditor of and stockholder in, and
authorized to make its investment in, the Company as provided herein; (B) it was not formed for the purpose of purchasing the
Notes; (C) the person signing this Subscription Agreement on behalf of such entity has been duly authorized by such entity to
do so and by her/his execution of the Subscription Agreement, the Subscription Agreement constitutes a valid and legally binding
obligation by the Subscriber; and (D) the Undersigned is duly organized and validly existing under the laws of its state of organization.
17 (p) If the Subscriber is an individual, she/he is over 21 years of age; or, if the Subscriber is a partnership, trust or other
entity, each equity owner of such entity is over 21 years of age. (q) The Undersigned has full power and authority to enter into
this Subscription Agreement and, upon execution by the Undersigned, the Subscription Agreement will constitute the Undersigned's
valid and legally binding obligation. (r) This Subscription Agreement, together with the Exhibits hereto, constitutes the entire
agreement of the parties hereto, and supersedes all prior understandings with respect to the subject matter hereof. (s) The address
set forth below is the Undersigned's (if an individual) true and correct residence, and the Undersigned has no current intention
of becoming a resident of any other state or jurisdiction prior to the date on which payment in full for her/his Note will be
made. If the Undersigned is a partnership, corporation or other entity, such address is such entity's principal place of business.
(t) All information which the Subscriber has heretofore furnished to the Company in this Subscription Agreement or any Exhibits
hereto, is correct and complete as of the date of this Subscription Agreement and if there should be any material change in such
information prior to her/his purchase of the Notes she/he will immediately furnish such revised or corrected information to the
Company. (u) The foregoing representations, warranties and agreements shall survive the date of this Subscription Agreement and
the final Closing of the Offering. THE UNDERSIGNED ACKNOWLEDGES THAT THE ABOVE SUBSCRIPTION AGREEMENT CONSISTS OF 18 PAGES AND
ALSO INCLUDES EXHIBITS A THROUGH C. (Subscription Page to follow) 18 Subscription Page A. SUBSCRIPTION: Number ofNotes purchased
Aggregate Purchase Price B. MANNER IN WHICH TITLE IS TO BE HELD (Please check One): 1. ❑
Individual 2.
❑
Joint Tenants with Rig
Indemnity ht of Survivorship 3. ❑
Community Property
4. ❑
Tenants in Common 5.
❑
Corporation/Partnership/
Limited Liability Company 6. ❑
IRA 7. ❑
Trust/Estate/Pension
or Profit Sharing Plan, and date opened: 8. ❑
As a Custodian
for UGMA (State) 9. ❑
Married with
Separate Property 10. ❑
Keogh 11. ❑
Tenants by Entirety
12. ❑
Other: C. TITLE: PLEASE
GIVE THE EXACT AND COMPLETE NAME IN WHICH TITLE TO THE NOTES ARE TO BE HELD: (signature page to follow) 19 Signature Page IN WITNESS
WHEREOF, the Purchaser has executed this Subscription Agreement on the day of , 2019. Name (of Entity if applicable): Signature:
Signature: Name: Name: Title (if applicable): Address: Street or City State Zip Address for Notices: Street or City State Zip
P.O. Box No. Facsimile Number: Email Address: Social Security or Federal Tax ID Number: ACCEPTED ON BEHALF OF THE COMPANY: INVENTABIOTECH
INC. BY: Dated: Name: Title:Exhibit 10.2

 

 

 

 

 

    	 	 	 

    	 

    

 

 

 

    	 	 	 

    	 

    

 

 

 

    	 	 	 

    	 

    

 

 

 

Inventa

80Tcch

Employment Agreement

Title: Interim CEO
at InventaBioTech. Employed Full Time and based in NY (no requirement to relocate to San

Antonio). Note:
The Interim CEO will to disclose his current Divine activities to allow him to carve out and

continue these actives
while functioning as a full time Inventa Biotech CEO. The position will require a board

seat.

Duration: Until
a permanent CEO is employed. Maximum duration of 6 months from date of signature. The

agreement will be
open for review at that time

Release Agreement:
As part of this employment agreement, the Company will provide the Interim CEO with a

Release agreement,
Exhibit I.

Key Duties, Role,
Responsibilities and Accountabilities:

• Raise additional
funding ($2M minimum) within 6 months of employment

• Identify,
recommend and appoint with the Board a new CEO

• Immediately
recommend workforce adjustments and stabilize the company to minimize expenses

• Manage and
prioritize all expenses to meet company goals

• Present a
new business plan to maximize revenues and build for the future

• Close current
and identify new M&A target companies to increase company value

• Manage all
legal, financial and SEC reporting function (internal and external). Move company

towards NASDAQ listing

• The Interim
CEO will report to the Board, all other employees with report to the Interim CEO

without exception.

• The interim
CEO will chair and manage Monthly Board meeting/conference calls

Compensation Outline:

Salary: $11,000/
month until a minimum of $2MM in new funding is raised. When the $2MM is closed upon,

salary will increase
to $25,000/month for the remainder of his contract

Cash Bonus: For
achievement of additional set goals, to be mutually agreed upon by the Interim CEO and the

Board of Directors,
and memorialized and added to this agreement, bonus of up to 25% ($75,000) of the full

annual salary ($300K)
will be paid at the end of the contract period (at 6 months). Bonus amount will be at the

discretion of the
Board.

Sign on stock options:
100,000 stock options vesting immediately

Additional stock
options: Additional stock options will be offered, to vest immediately, upon the

achievement of the
following milestones: 100,000 stock options for each new $lM raised beyond the

minimum of $3M,
up to a maximum of $7M. Raise $3MM and receive an additional 100,000 stock options,

raise $7MM and receive
an additional 500,000 stock options

Benefits: Are not
required as part of this agreement

Paid Vacation: 2
days/month

Severance: Severance
is not offered

T&E: Reasonable
reimbursement of expenses

Reasonable and reimbursable
expenses will include trips to San Antonio, trips to various funders, as well as

living/hotel, transportation
costs associated with those endeavors. Additional T&E will be allowable upon

agreement with the
Board.

Notice period: 3D
days

Inventions.

A. Inventions Retained
and Licensed. Represent and warrant that there are no such Prior

Inventions..

B. Assignment of
Inventions. I agree that I will promptly make full written disclosure to the

Company, will hold
in trust for the sole right and benefit of the Company, and hereby assign to the Company,

or its designee,
all my right, title, and interest in and to any and all inventions, original works of authorship,

mask works, developments,
concepts, improvements, designs, discoveries, ideas, trademarks and trade

secrets, whether
or not patentable or registrable under copyright or similar laws, which I may solely or jointly

conceive, create,
develop or reduce to practice, or cause to be conceived or created or developed or reduced

to practice, during
the period of time I am in the employ of the Company (collectively, "Inventions"), together

with all patent,
copyright, mask work, trademark, trade secret, and other intellectual property rights therein,

except as provided
in Section DError! Reference source not found. below. I further acknowledge that all

original works of
authorship (i) which are made by me (solely or jointly with others) within the scope of and

during the period
of my employment with the Company and (ii) which are protectable by copyright are "works

made for hire"
as that term is defined in the United States Copyright Act, and the Company is the author and

owner of such original
works of authorship and all copyrights in and to the same. I understand and agree that

the decision whether
or not to commercialize or market any Invention is within the Company's sole discretion

and for the Company's
sole benefit and that no royalty will be due to me as a result of the Company's efforts

to commercialize
or market any such Invention.

C. Inventions Assigned
to the United States. I agree to assign to the United States

government all my
right, title, and interest in and to any and all Inventions whenever such full title is required

to be in the United
States by a contract between the Company and the United States or any of its agencies.

D. Maintenance of
Records. I agree to keep and maintain adequate and current written

records of all Inventions
during the term of my employment with the Company. The records will be in the form

of notes, sketches,
drawings and any other format that may be specified by the Company. The records will be

available to and
remain the Company's sole property at all times.

E. Potent and Copyright
Registrations. I agree to assist the Company, or its designee, at the

Company's expense,
in every proper way to secure the Company's rights in any Inventions and any copyrights,

patents, mask work
rights or other intellectual property rights relating thereto in any and all countries,

including the disclosure
to the Company of all pertinent information and data with respect thereto, and the

execution of all
applications, specifications, oaths, assignments and all other instruments that the Company

deems necessary
in orderto apply for and obtain such rights and in order to assign and convey to the Company,

its successors,
assigns, and nominees the sole and exclusive rights, title and interest in and to such Inventions,

and any copyrights,
patents, mask work rights or other intellectual property rights relating thereto. I further

Date

Date

Alan H. Dean, Chairman
of the Board

Steven W. C e.&
/'

agree that my obligation
to execute or cause to be executed, when it is in my power to do so, any such

instrument or papers
shall continue after the termination of my employment with the Company and the

termination of this
Agreement. If the Company is unable because of my mental or physical incapacity or for

any other reason
to secure my signature to appl or or to pursue any application for any United States or

foreign patents
or copyright registrations coverin' any Inventions or original works of authorship assigned to

the Company as above,
then i hereby ir~cably, designate and appoint the Company and its duly authorized

officers and agents
as my agent and attofn£! i act, to act for and on my behalf and stead to execute and file

any such applications
and to do aW;;th f')a';o/fully permitted acts to further the prosecution and issuance of

letters patent or
copyright regist;:atloS hefeon with the same legal force and effect as if executed by me.

EXHIBIT 1

RELEASE AGREEME~T

This is the Release
Agreement (the "Agreement") as referenced in paragraph of the Interim CEO Employment

Agreement by and
between InventaBioTech, Inc. (the "Company") and Steven W. Charest (the "Executive"),

dated as of January
31, 2019(the "Employment Agreement").

Date

I. Release of Claims.
The Company, its affiliated and related entities, their predecessors,

successors and assigns,
their employee benefit plans and fiduciaries of such plans, and the current and former

officers, directors,
employees, attorneys, accountants and agents of any and all of the foregoing in their official

and personal capacities
(collectively referred to as the "Releasees") voluntarily releases and forever discharges

the Executive, from
all claims, demands, debts, damages and liabilities of every name and nature, known or

unknown ("Claims")
that, as of the date when the Executive signs this Agreement.

2. Other Terms.

(a) legal Representation;.
The Executive acknowledges that he has been advised to

discuss all aspects
of this Agreement with his attorney, that he has carefully read and fully understands all of

the provisions of
this Agreement and that he is voluntarily entering into this Agreement.

(b) Binding Nature
of Release This Agreement shall be binding upon the parties and their

heirs, administrators,
representatives, and successors.

(c) Amendment. This
Agreement may be amended only upon a written agreement

executed by the
Executive and the Company.

(d) Severability.
In the event that at any future time it is determined by an arbitrator or

court of competent
jurisdiction that any covenant, clause, provision or term of this Agreement is illegal, invalid

or unenforceable,
the remaining provisions and terms of this Agreement shall not be affected thereby and the

illegal, invalid
or unenforceable term or provision shall be severed from the remainder of this Agreement. In

the event of such
severance, the remaining covenantslhall be binding and enforceable.

(e) Governing law
and Interpretation. This Agreement shall be deemed to be made and

entered into in
the state of Texas, and shall in al(res6ects be interpreted, enforced and governed under the

laws of the state
of Texas, without giving,etf. {, to'the conflict of laws provisions of Washington law. The

language of all
parts of this Agreement W'a)n ~cases be construed as a whole, according to its fair meaning,

and not strictly
for or against the Comp-arty r the Executive.

So agreed. A /

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]